HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warning Streak Continues, Underscoring Risky Products And Claims

This article was originally published in The Rose Sheet

Executive Summary

Agency has been turning up the heat this summer on skin-care marketers, posting two more July warning letters issued to companies for use of unapproved drug claims. Firms that sell anti-aging serums, eye-area formulas or anything promoted as an “anti-wrinkle” solution should review their claims to ensure compliance.


Related Content

FDA Warning Letters Target Skin Brighteners, Muscle-Relaxing Claims
FDA Warning Letter Barrage Continues With Five More To Close July
FDA Not On Vacation: Warning Letter Burst Targets More Skin-Care Marketers
FDA Warning Letter Recipients: Where Are Their Claims Now?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts